Whereas, Ennishi et al. focused on GCB DLBCL to develop a signature derived from genes differentially expressed between MYC/BCL2 double-hit and non-double-hit GCB-DLBCLs. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.